• 90
  • 7
  • 收藏

Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI

Tiger Newspress2021-12-13

Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).

ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论7

  • Piret
    ·2021-12-14
    Ok
    回复
    举报
  • 股市搜搜搜
    ·2021-12-13
    Good
    回复
    举报
    收起
  • 来人
    ·2021-12-13
    Nice
    回复
    举报
    收起
    • k1wong
      K
      2021-12-14
      回复
      举报
  • betka
    ·2021-12-13
    Great!
    回复
    举报
  • Mml
    ·2021-12-13
    Great
    回复
    举报
    收起
    • Phyusin
      Really
      2021-12-13
      回复
      举报
    • xxbbew
      Ok
      2021-12-13
      回复
      举报
  • CYKuan
    ·2021-12-13
    biotech company share value always in line with the effectiveness of their drugs 
    回复
    举报
    收起
    • Prosperity88
      weeeeeeeeeeerrrrrrellllllllllllllllllllllllll
      2021-12-13
      回复
      举报
    • Mml
      I see
      2021-12-13
      回复
      举报
  • EeHoe
    ·2021-12-13
    gl guys
    回复
    举报
 
 
 
 

热议股票

 
 
 
 
 

7x24